论文部分内容阅读
近年来,越来越多的结核病患者对异烟肼、利福平等常规化疗效果差,痰菌不易阴转,传染期长,其原因为结核菌产生多重耐药,导致治疗困难,死亡率上升。本文就近3年来遇到的35例多重耐药性结核病(MDR-TB)患者,分析其产生原因,以提供临床注意。一、临床资料经过连续抗结核治疗6个月,痰涂片结核分枝杆菌仍为阳性的病例,痰培养对利福平、异烟肼产生耐药,称为MDR—TB。其中21例为院外经SHRE/HR方案治疗6个月后到本院就诊的患者,14例为在本院经HRZ/HR方案治疗6个月的患者。
In recent years, more and more patients with tuberculosis are ineffective on conventional chemotherapy such as isoniazid and rifampicin, and the sputum bacterium is not easily overcast and the infection period is long. The reason is that the tuberculosis bacteria produce multiple drug resistance, which leads to the difficulty of treatment and the increase of the mortality rate . In this paper, 35 patients with multidrug-resistant tuberculosis (MDR-TB) encountered in the past three years were analyzed for their causes to provide clinical attention. First, the clinical data After continuous anti-TB treatment for 6 months, sputum smear Mycobacterium tuberculosis is still positive cases, sputum culture of rifampicin, isoniazid resistant, known as MDR-TB. Of the 21 patients who were hospitalized with SHRE / HR regimen for 6 months, they were treated in our hospital and 14 patients were treated in our hospital with HRZ / HR regimen for 6 months.